SGMO vs. ATRA, CLLS, BLUE, ADAP, XOMA, CDXS, RIGL, ACHV, AGEN, and RGLS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Atara Biotherapeutics (ATRA), Cellectis (CLLS), bluebird bio (BLUE), Adaptimmune Therapeutics (ADAP), XOMA (XOMA), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), Achieve Life Sciences (ACHV), Agenus (AGEN), and Regulus Therapeutics (RGLS). These companies are all part of the "medical" sector.
Sangamo Therapeutics (NASDAQ:SGMO) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.
Sangamo Therapeutics currently has a consensus target price of $5.67, indicating a potential upside of 555.18%. Atara Biotherapeutics has a consensus target price of $355.50, indicating a potential upside of 3,395.58%. Given Atara Biotherapeutics' higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Sangamo Therapeutics.
Sangamo Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
Atara Biotherapeutics has a net margin of -671.70% compared to Sangamo Therapeutics' net margin of -1,749.06%. Atara Biotherapeutics' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics received 11 more outperform votes than Atara Biotherapeutics when rated by MarketBeat users. However, 67.35% of users gave Atara Biotherapeutics an outperform vote while only 62.41% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sangamo Therapeutics had 5 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Sangamo Therapeutics and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.76 beat Sangamo Therapeutics' score of 0.48 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Sangamo Therapeutics and Atara Biotherapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
